Interaction of heparins with fibroblast growth factors: Conformational aspects

Current Pharmaceutical Design

Volumn 13, Issue 20, 2007, Pages 2045-2056

  Guerrini, Marco ^a   Hricovíni, Miloš ^b   Torri, Giangiacomo ^a  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

FGF; Heparin; NMR spectroscopy; Oligosaccharide conformation; Protein carbohydrate interaction

Indexed keywords

ANGIOGENESIS INHIBITOR; BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLYCOSAMINOGLYCAN; HEPARIN; IDURONIC ACID; OLIGOSACCHARIDE; POLYSACCHARIDE; TETRASACCHARIDE;

AMINO ACID SEQUENCE; ANGIOGENESIS; BINDING SITE; CRYSTAL STRUCTURE; MOLECULAR MODEL; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARBOHYDRATE CONFORMATION; FIBROBLAST GROWTH FACTORS; HEPARIN; HEPARITIN SULFATE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 34447265278     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039733     Document Type: Review

References (64)

1. Conrad E. Heparin binding proteins. Academic, New York 1998; 301-48.
2. Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Proc Natl Acad Sci USA 1999; 96: 3658-63.
3. Venkataraman G, Sasisekharan, V, Herr AB, Ornitz DM, Waksman G, Cooney CL, et al. Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA 1996; 93: 845-50.
4. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signaling: a structural view. Curr Opin Struct Biol 2001; 11: 629-34.
5. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin-heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 1993; 268: 23898-905.
6. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulphate using an octasaccharide library. J Biol Chem 2004; 279: 12346-54.
7. Casu B, Choay J, Ferro DR, Gatti G, Jacquinet JC, Petitou M, et al. Controversial glycosaminoglycan conformations. Nature 1986; 322: 215-6.
8. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, et al. Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res 1990; 195: 157-67.
9. Ragazzi M, Ferro DR, Provasoli A. A force-field study of the conformational characteristics of the iduronate ring. J Comput Chem 1986; 7: 105-12.
10. Ferro DR, Provasoli A, Ragazzi M, Torri G, Casu B, Gatti G, et al. Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic mono- and oligosaccharides. J Am Chem Soc 1986; 108: 6773-8.
11. Hricovíni M, Guerrini M, Bisio A. Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. Eur J Biochem 1999; 261: 789-801.
12. Petitou M, Jaurand G, Derrion M, Duchaussoy P, Choay J. The 1st total synthesis of the antithrombin-III binding-site of porcine mucosa heparin. Bioorg Med Chem Lett 1991; 1: 95-8.
13. Ernst S, Venkataraman G, Sasisekharan V, Langer R, Cooney CL, Sasisekharan R. Pyranose ring flexibility. Mapping of physical data for iduronate in continuous conformational space J Am Chem Soc 1998; 120: 2099-107.
14. Casu B. Structure, active domains of heparin. In: Garg HG, Linhardt RJ, Hales CA Eds, Chemistry and biology of heparin and heparan sulfate. Elsevier 2005; 461.
15. Mulloy B, Forster M.J. Conformation and dynamics of heparin and heparan sulfate. Glycobiology 2000; 10: 1147-56.
16. Hricovíni M, Nieto PM, Torri G. In: Jimenez-Barbero J, Peters T Eds, NMR spectroscopy of glycoconjugates, Wiley-VCH 2002; 189-229.
17. Ragazzi M, Ferro DR, Perly B, Sinay P, Petitou M, Choay JM. Conformation of the pentasaccharide corresponding to the binding-site of heparin for antithrombin. Carbohydr Res 1990; 195: 169-85.
18. Mikhailov D, Mayo KH, Vlahov IR, Toida T, Pervin A, Linhardt RJ. NMR solution conformation of heparin-derived tetrasaccharide. Biochem J 1996; 318: 93-102.
19. Mikhailov D, Linhardt RJ, Mayo KH. NMR solution conformation of heparin-derived hexasaccharide Biochem J 1997; 328: 51-61.
20. Mulloy B, Forster MJ, Jones C, Davies DB. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem J 1993; 293: 849-58.
21. Atkins EDT, Nieduszynski IA. In: Bradshaw RA, Weesler S Eds, Heparin structure function and clinical implications. Plenum Press New York 1975; 19.
22. Hricovíni M, Torri G. Dynamics in aqueous solutions of the pentasaccharide corresponding to the binding site of heparin for antithrombin III studied by NMR relaxation measurements. Carbohydr Res 1995; 268: 159-75.
23. Angulo J, Hricovíni M, Gairi M, Guerrini M, de Paz JL, Ojeda R, et al. Dynamic properties of biologically active synthetic heparin-like hexasaccharides. Glycobiology 2005; 15: 1008-15.
24. Hricovíni M, Guerrini M, Torri G, Casu B. Motional properties of E. coli polysaccharide K5 in aqueous solution analyzed by NMR relaxation measurements. Carbohydr Res 1997; 300: 69-76.
25. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 2004; 47: 838-48.
26. Hricovini M, Guerrini M, Bisio A, Torri G, Petitou M, Casu B. Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J 2001; 359: 265-72.
27. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-88.
28. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science 1996; 271: 1116-20.
29. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol 2005; 12: 267-77.
30. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
31. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed 2002; 41: 390-412
32. Powel AK, Yates EA, Fernig DG, Turnbull JE. Interactions of heparin/ heparan sulfate with proteins: Appraisal of structural factors and experimental approaches. Glycobiology 2004; 14: 17R-30R.
33. DiGabriele AD, Lax I, Chen DI, Svahn CM, Jae M, Schlessinger J, et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 1998; 393: 812-7.
34. Plotnikov AN, Schlessinger J, Hubbard SH, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98: 641-50.
35. Plotnikov AN, Hubbard SH, Schlessinger J, Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000; 101: 413-24.
36. Pellegrini L, Burke DF, Von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000; 407: 1029-34
37. Ogura K, Nagata K, Hatanaka H, Habuchi H, Kimata K, Tate S, et al. Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. J Biomol NMR 1999; 13: 11-24.
38. Moy FJ, Safran M, Seddon AP, Kitche D, Böhlen, P, Aviezer D, et al. Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 1997; 36: 4782-91.
39. Lam K, Rao VSR, Qasba PK. Molecular modelling studies on binding of bFGF to heparin and its receptor FGFR1. J Biomol Struct Dyn 1998; 15: 1009-27.
40. Harmer NJ, Robinson CJ, Adam LE, Ilag LL, Robinson CV, Gallagher JT, et al. Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. Biochem J 2006; 393: 741-8.
41. Pineda-Lucena A, Jiménez MA, Lozano RM, Nieto JL, Santoro J, Rico M, et al. Three-dimensional structure of acidic fibroblast growth factor in solution: effects of binding to a heparin functional analog. J Mol Biol 1996; 264: 162-78.
42. Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, et al. Three-dimensional structures of acidic and basic fibroblast growth factors. Science 1991; 251: 90-3.
43. Pey DA, Vives RR, Hyde P, Gallagher JT. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dipendent on specific structural features: differential requirements for the modulation of FGF1 and FGF-2. Glycobiology 2000; 10: 1183.
44. Angulo J, Ojeda R, Paz JL, Lucas R, Nieto PM, Lozano R, et al. The activation of fibroblast growth factors (FGFs) by glycosaminoglycans: influence of the sulfation pattern on the biological activity of FGF-1. Chembiochem 2004; 5: 55-61.
45. 0 conformations of a bioactive heparin-like hexasaccharide J Am Chem Soc 2005; 127: 5778-9.
46. Poletti L, Lay L, Fleischer M, Vogel C, Guerrini M, Torri G, et al. A rational approach to heparin-related fragments 2 synthesis of differently sulfated tetrasaccharides as potential ligands for Fibroblast Growth Factors. Eur J Org Chem 2001; 14: 2727-34.
47. Guerrini M, Agulles T, Bisio A, Hricovíni M, Lay L, Naggi A, et al. Minimal heparin/heparan sulfate sequences for binding fibroblast growth factor 1. Biochem Biophys Res Commun 2002; 292: 222-30.
48. Rusnati M, Coltrini D, Caccia P, Dell'Era P, Zoppetti G, Oreste P, et al. Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 1994; 203: 450-8.
49. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. Heparan sulphate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 1998; 273: 22936-42.
50. Kovensky J, Duchaussoy P, Bono F, Salmivirta M, Sizun P, Herbert JM, et al. A synthetic heparan sulfate pentasaccharide, exclusively containing L-Iduronic acid, displays higher affinity for FGF-2 its D-Glucuronic acid-containing isomers. Bioorg Med Chem 1999; 7: 1567-80.
51. Delehedde M, Lyon M, Gallagher JT, Rudland PS, Fernig DG. Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochem J 2002; 366: 235-44.
52. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Molecular Cell 2000; 6: 743-50.
53. Ornitz MD, Herr AB, Nilsson M, Westman J, Svhan CM, Waksman G. FGF binding and FGF receptor activation by synthetic heparan derived di- and tetrasaccharides. Science 1995; 268: 432-6.
54. Guglieri S, Hricovini M, Raman R, Sasisekharan R, Polito L, Guerrini M. NMR solution conformation of heparin like tetrasaccharide bound to the growth factor FGF2. Proc Natl Acad Sci USA (submitted).
55. Schlessinger J. Common and distinct elements in cellular signalling via EGF and FGF receptors. Science 2004; 306: 1506-7.
56. Naggi A. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. In: Garg HG, Linhardt RJ, Hales CA Eds, Chemistry and biology of heparin and heparan sulfate. Elsevier 2005; 461.
57. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, et al. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochem 2002; 41: 10519-28.
58. Hricovíni M, Guerrini M, Naggi A, Torri G, Casu B. Dynamics of heparin and heparin derivative spaced by glycol-split urinate residues analyzed by NMR relaxation measurements. (Manuscript in preparation).
59. Moseley HNB, Curto EV, Krishna NR. Complete relaxation and conformational exchange matrix (CORCEMA) analysis of NOESY spectra of interacting systems; two-dimensional transferred NOESY. J Magn Reson 1995; B108: 243-61.
60. Faham S, Linhardt RJ, Rees DC. Diversity does make a difference: fibroblast growth factor-heparin interactions. Curr Opin Struct Biol 1998; 8: 578-86.
61. Hricovini M. B3LYP/6-311++G** study of structure and spin-spin coupling constant in methyl 2-O-sulfo-α-L-iduronate. Carbohydr Res 2006; 341: 2575-80.
62. Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005; 11(30): 3943-71.
63. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des 2005; 11(19): 2489-99.
64. Zartler ER, Shapiro MJ. Protein NMR-based screening in drug discovery. Curr Pharm Des 2006; 12(31): 3963-72.